Kristen Robillard, MD
Family Medicine · Hamburg, NYNPI 1508800491
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. GSK accounts for 82.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $7,328 and has fallen 96.3% since, to $270 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $100.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- AstraZeneca$550
- AbbVie$270
- Novo Nordisk$173
- Lilly USA, LLC$73
- Amgen$70
- plus $372 from 15 others
Across 2 payments — averaging $1382.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$3K
What the payments were for
- Consulting fees$5,00058%
- Grants$5957%
- Travel & lodging$1,02612%
- Food & beverage$1,98123%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $7,115 |
| AstraZeneca | 11 | $550 |
| AbbVie | 9 | $270 |
| Novo Nordisk | 10 | $173 |
| Lilly USA, LLC | 4 | $73 |
| Amgen | 4 | $70 |
| Exact Sciences | 3 | $54 |
| Abbott | 2 | $40 |
| Seqirus USA Inc | 2 | $36 |
| Merck | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| Pfizer | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Foundation Fusion Solutions, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$242
- FARXIGA$222
- VRAYLAR$125
- BREZTRI$103
- AIRSUPRA$103
How this compares
$8,623 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 138 | $117,804 |
| OzempicSemaglutide | 67 | $107,037 |
| MounjaroTirzepatide | 69 | $88,115 |
| RybelsusSemaglutide | 43 | $69,404 |
| JardianceEmpagliflozin | 59 | $68,775 |
| EliquisApixaban | 56 | $54,313 |
| FarxigaDapagliflozin Propanediol | 45 | $40,495 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $35,133 |
| ProliaDenosumab | 20 | $34,152 |
| SynjardyEmpagliflozin/Metformin Hcl | 33 | $34,129 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $32,390 |
| XareltoRivaroxaban | 31 | $28,598 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $22,402 |
| InvokanaCanagliflozin | 19 | $21,948 |
| TrulicityDulaglutide | 15 | $14,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $173 | $176,441110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $7,115 | $148,196206 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $14 | $112,953106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $102,56484 claims |
| PfizerEliquis | $22 | $54,31356 claims |
| Johnson & JohnsonXarelto, Invokana | $13 | $50,54650 claims |
| AstraZenecaFarxiga | $550 | $40,49545 claims |
| AmgenProlia | $70 | $34,15220 claims |
| AbbVieLinzess, Synthroid | $270 | $15,88676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Hamburg
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.